TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31373696

Group type: EXPERIMENTAL
Intervention: Orally administered glucocorticosteroids preoperatively
Number of subjects: 52

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) without preoperative steroids
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative olfactory dynamics after ESS
Number of subjects: 52
Study: 31217344

Group type: EXPERIMENTAL
Intervention: Palbociclib + letrozole (palbociclib: 125 mg daily; 3 weeks on/1 week off; letrozole: 2.5 mg daily continuously)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo + letrozole (letrozole: 2.5 mg daily continuously)
Number of subjects: 666
Study: 27979064

Group type: EXPERIMENTAL
Intervention: Pomegranate seed oil (0.5%, 1.0%, 1.5%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (2.5% sunflower oil)
Number of subjects: 40
Study: 25103680

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA) aiming at peak Edi between 5 and 15 µV
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 81
Study: 23314589

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise (CSE)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Spinal Flexibility Exercise (SFE)
Number of subjects: 46
Study: 21942614

Group type: EXPERIMENTAL
Intervention: Lutein
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 18644124

Group type: EXPERIMENTAL
Intervention: MonoMax suture material
Number of subjects: 150

Group type: COMPARATOR
Intervention: Monoplus and PDS (historical control)
Number of subjects: 150
Study: 16391574

Group type: EXPERIMENTAL
Intervention: 7-day diet record (7-DDR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire (FFQ)
Number of subjects: 65
Study: 14704262

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (0.05 mg/d) plus progestin (2.5 mg/d; n = 31)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.625 mg/d) plus progestin (2.5 mg/d; n = 30)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 82
Study: 11412219

Group type: EXPERIMENTAL
Intervention: Comorbidity (one concomitant disease)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Comorbidity (two or more diseases)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Poor differentiation of the tumour
Number of subjects: 894
Study: 9220037

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nifedipine coat-core (CC)
Number of subjects: 91
Study: 8432777

Group type: EXPERIMENTAL
Intervention: Diet with 25% fat and 60% carbohydrate (CHO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet with 40% fat and 45% carbohydrate (CHO)
Number of subjects: 8
Study: 2951031

Group type: EXPERIMENTAL
Intervention: Butorphanol (40 micrograms X kg‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fentanyl (2.0 micrograms X kg‐1)
Number of subjects: 36
Study: 29234884

Group type: EXPERIMENTAL
Intervention: Manual therapy combined with steroid injection (Group 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Steroid injection (Group 2)
Number of subjects: 44
Study: 26909885

Group type: EXPERIMENTAL
Intervention: Gaviscon Advance 10 mL four times a day
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 24982236

Group type: EXPERIMENTAL
Intervention: Monotherapy with DFX 30 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Monotherapy with DFP 80 mg/kg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined therapy with DFX 30 mg/kg and DFP 40 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Concurrent therapy with DFX 30 mg/kg and DFP 80 mg/kg
Number of subjects: 8
Study: 22156009

Group type: EXPERIMENTAL
Intervention: Bilateral injection (C: 6 mL/s; D: 8 mL/s)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Unilateral injection (A: 4 mL/s; B: 6 mL/s)
Number of subjects: 180
Study: 20728299

Group type: EXPERIMENTAL
Intervention: Telephonic support program for new B-MAT patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B-MAT (buprenorphine medication-assisted treatment)
Number of subjects: 0
Study: 19167585

Group type: EXPERIMENTAL
Intervention: Prefilled insulin delivery device (NovoMix 30 FlexPen)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Reusable insulin delivery device (HumaPen Luxura)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall preference for devices
Number of subjects: 61

Group type: COMPARATOR
Intervention: Injection time excluding cartridge insertion for HL device
Number of subjects: 61
Study: 11174477

Group type: EXPERIMENTAL
Intervention: Estradiol plus sequential norethindrone acetate
Number of subjects: 16
Study: 9725047

Group type: EXPERIMENTAL
Intervention: MTX, 5-FU, and THP (Group A)
Number of subjects: 71

Group type: COMPARATOR
Intervention: 5-FU alone (Group B)
Number of subjects: 71
Study: 8199143

Group type: EXPERIMENTAL
Intervention: Broad retractor
Number of subjects: 300

Group type: COMPARATOR
Intervention: Howarth's periosteal elevator
Number of subjects: 300
Study: 3379987

Group type: EXPERIMENTAL
Intervention: Quality assurance intervention including predeveloped quality assurance packages and consultant services.
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Control group (no quality assurance intervention).
Number of subjects: 1525
Study: 31504424

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study: 30957447

Group type: EXPERIMENTAL
Intervention: Surround needling
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Acupoint injection
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Combined group (surround needling + acupoint injection)
Number of subjects: 99
Study: 28416501

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU, twice daily for 2 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (twice daily for 2 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26091202

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1000 IU/d
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 22972566

Group type: EXPERIMENTAL
Intervention: Ketofol (1:1 mixture of 5 mg/ml ketamine and 5 mg/ml propofol)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol 0.15 ml/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study: 21938266

Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 46

Group type: COMPARATOR
Intervention: Adults
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 18959799

Group type: EXPERIMENTAL
Intervention: Participatory Ergonomics (PE)
Number of subjects: 5759

Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 5759
Study: 17038756

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for mothers with problem drinking
Number of subjects: 25
Study: 12949687

Group type: EXPERIMENTAL
Intervention: Epigam (1 tablet, 6 times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ranitidine (150 mg, 2 times a day)
Number of subjects: 20
Study: 10836487

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9055055

Group type: EXPERIMENTAL
Intervention: Slow-release gemfibrozil, 1200 mg once daily
Number of subjects: 395

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 395
Study: 8338511

Group type: EXPERIMENTAL
Intervention: Low-air-loss bed
Number of subjects: 84

Group type: COMPARATOR
Intervention: 10-cm corrugated foam mattress
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-air-loss bed (deep ulcers)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 10-cm corrugated foam mattress (deep ulcers)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-air-loss bed (superficial ulcers)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 10-cm corrugated foam mattress (superficial ulcers)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-air-loss bed (combined cure probability)
Number of subjects: 84
Study: 31094588

Group type: EXPERIMENTAL
Intervention: Desogestrel 75 µg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual contraceptive
Number of subjects: 150
Study: 29869351

Group type: EXPERIMENTAL
Intervention: Football
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Circuit-training
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 9
Study: 26290587

Group type: EXPERIMENTAL
Intervention: Patient-initiated DMARD self-monitoring service
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 25236993

Group type: EXPERIMENTAL
Intervention: Desmopressin orally disintegrating tablet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 22385692

Group type: EXPERIMENTAL
Intervention: Slow heating regimen
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Slow cooling regimen
Number of subjects: 54

Group type: COMPARATOR
Intervention: Heating regimen
Number of subjects: 54
Study: 20130241

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus rituximab
Number of subjects: 103

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 103
Study: 18641372

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 12
Study: 16988138

Group type: EXPERIMENTAL
Intervention: Fortified milk (FM) with 5.8 mg iron as ferrous gluconate, 5.28 mg zinc as zinc oxide, and 48 mg ascorbic acid per 400 mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfortified milk (NFM) with 0.2 mg iron, 1.9 mg zinc, and 6.8 mg ascorbic acid per 400 mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fortified milk (FM)
Number of subjects: 0
Study: 12729425

Group type: EXPERIMENTAL
Intervention: 10-mg warfarin initiation nomogram
Number of subjects: 201

Group type: COMPARATOR
Intervention: 5-mg warfarin initiation nomogram
Number of subjects: 201
Study: 10979111

Group type: EXPERIMENTAL
Intervention: Celecoxib, 400 mg twice per day (n = 3987)
Number of subjects: 8059

Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, 800 mg 3 times per day; n = 1985) or diclofenac, 75 mg twice per day (n = 1996)
Number of subjects: 8059
Study: 9038440

Group type: EXPERIMENTAL
Intervention: Thoracocervical epidural block (lignocaine 1%)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lumbar epidural block (lignocaine 1.5%)
Number of subjects: 36
Study: 1573368

Group type: EXPERIMENTAL
Intervention: Questionnaires with questions about housing tenure
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Questionnaires without questions about housing tenure
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Questionnaires with questions about ethnic origin
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Questionnaires without questions about ethnic origin
Number of subjects: 10000
Study: 4070708

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 24
Study: 31498784

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) package for neonatal resuscitation
Number of subjects: 89014
Study: 29943384

Group type: EXPERIMENTAL
Intervention: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil, prescribed for 3 months (20 suppositories at each menstrual cycle)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo vaginal suppository, prescribed for 3 months (20 suppositories at each menstrual cycle)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo vaginal suppository
Number of subjects: 60
Study: 26873229

Group type: EXPERIMENTAL
Intervention: Daclizumab HYP (150 mg SC every 4 weeks)
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Daclizumab HYP (100-300 mg SC)
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Daclizumab HYP
Number of subjects: 1657
Study: 24509626

Group type: COMPARATOR
Intervention: Simulated altitude at sea level
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simulated altitude at 2000 m
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simulated altitude at 3000 m
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simulated altitude at 4000 m
Number of subjects: 10
Study: 23600304

Group type: EXPERIMENTAL
Intervention: Dendritic cell autovaccine loaded with autologous tumor cell lysate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard DC-autovaccine
Number of subjects: 0
Study: 21171135

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study: 17583594

Group type: EXPERIMENTAL
Intervention: A‐line auditory‐evoked potential monitor (Group AAI, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Aspect A‐2000 bispectral index monitor (Group BIS, n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: A‐line auditory‐evoked potential monitor (Group AAI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Aspect A‐2000 bispectral index monitor (Group BIS)
Number of subjects: 200
Study: 16381256

Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cisatracurium
Number of subjects: 60

Group type: COMPARATOR
Intervention: vecuronium
Number of subjects: 60
Study: 12195876

Group type: EXPERIMENTAL
Intervention: Lamivudine and famciclovir combination therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lamivudine and famciclovir combination therapy with IFN-alpha 2b
Number of subjects: 20
Study: 10096821

Group type: EXPERIMENTAL
Intervention: House dust mite avoidance therapy (including allergen-impermeable encasement of mattresses and other strategies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: House dust mite exposure
Number of subjects: 0
Study: 7534055

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (non-heparin-coated) cardiopulmonary bypass
Number of subjects: 36
Study: 2240543

Group type: EXPERIMENTAL
Intervention: Tracheal tube orientation of -90 degrees (bevel facing posteriorly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tracheal tube orientation of 0 degrees (bevel facing left)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presence of a laryngoscope during intubation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Laryngoscope left in mouth while rail-roading a tube over the bougie
Number of subjects: 100
Study: 678387

Group type: EXPERIMENTAL
Intervention: 160 mg long‐acting capsule formulation (LA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80 mg twice a day regimen (CP80)
Number of subjects: 12
Study: 30943777

Group type: EXPERIMENTAL
Intervention: Accelerated corneal cross-linking (18 mW/cm2, 5 min)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard corneal cross-linking (3 mW/cm2, 30 min)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Accelerated corneal cross-linking
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard corneal cross-linking
Number of subjects: 62
Study: 30309970

Group type: EXPERIMENTAL
Intervention: Sequential DMARD-monotherapy (sulfasalazine or methotrexate)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination therapy MTX + 6 weeks prednisolone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination therapy MTX + etanercept
Number of subjects: 94
Study: 28925749

Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation programme for 6 months
Number of subjects: 126

Group type: COMPARATOR
Intervention: No tele-intervention
Number of subjects: 126
Study: 25710801

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (SC) 1600 mg, three times a day
Number of subjects: 117
Study: 23484743

Group type: EXPERIMENTAL
Intervention: FSRS curriculum (Experimental Group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Crossover group (Control Group)
Number of subjects: 53
Study: 21849147

Group type: EXPERIMENTAL
Intervention: Mailuo Shutong Granule
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Hirudoid cream
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined therapy (Mailuo Shutong Granule + Hirudoid cream)
Number of subjects: 108
Study: 19433997

Group type: EXPERIMENTAL
Intervention: Team care with proactive clinical pharmacist services (medication history, patient-care round participation, resolution of drug-related issues, discharge counseling)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Team care with proactive clinical pharmacist services
Number of subjects: 452

Group type: COMPARATOR
Intervention: Usual care with traditional reactive clinical pharmacist services
Number of subjects: 452
Study: 16807001

Group type: EXPERIMENTAL
Intervention: Fluoropolymer-coated Dacron grafts
Number of subjects: 198

Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 198
Study: 14616458

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: oxybutynin IR 3 mg three times daily
Number of subjects: 608

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 608
Study: 10964190

Group type: EXPERIMENTAL
Intervention: Systematized education on HIV/AIDS
Number of subjects: 141
Study: 8813791

Group type: EXPERIMENTAL
Intervention: Straight anastomosis
Number of subjects: 33

Group type: COMPARATOR
Intervention: Colonic J pouch anastomosis
Number of subjects: 33
Study: 1359166

Group type: EXPERIMENTAL
Intervention: Timing with priming (0.005 mg.kg‐1 vecuronium as priming doses followed by 0.15 mg.kg‐1 vecuronium)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Timing (0.15 mg.kg‐1 vecuronium)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 4014048

Group type: EXPERIMENTAL
Intervention: milrinone
Number of subjects: 14
Study: 30184110

Group type: EXPERIMENTAL
Intervention: JNJ‐9375 (250 μg/mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: JNJ‐9375 (2.5, 25, and 250 μg/mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bivalirudin (6 μg/mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30898238

Group type: EXPERIMENTAL
Intervention: Ganglion plexus (GP) ablation
Number of subjects: 240
Study: 28122529

Group type: EXPERIMENTAL
Intervention: Monetary costs of Alzheimer's disease (AD)
Number of subjects: 2500
Study: 26749229

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 97
Study: 23233713

Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Melphalan-prednisone (MP)
Number of subjects: 682
Study: 21787883

Group type: EXPERIMENTAL
Intervention: Ovulation induction (OI) with aromatase inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ovulation induction (OI) with gonadotropins or clomiphene citrate
Number of subjects: 0
Study: 19340902

Group type: EXPERIMENTAL
Intervention: 300 mg of oral allopurinol at 15 h and 3 h before ERCP
Number of subjects: 170

Group type: COMPARATOR
Intervention: Oral placebo at the same times as the allopurinol group
Number of subjects: 170
Study: 16957651

Group type: COMPARATOR
Intervention: mini-subvastus approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: quadriceps-sparing approach
Number of subjects: 60
Study: 15103755

Group type: EXPERIMENTAL
Intervention: Baseline serum concentrations of prolactin in breast cancer patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic patients with metastatic breast cancer
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Serum concentration of prolactin before treatment in hyperprolactinemic patients
Number of subjects: 46
Study: 11704877

Group type: EXPERIMENTAL
Intervention: Wearing glasses from the age of six months
Number of subjects: 289

Group type: COMPARATOR
Intervention: Not wearing glasses (control group)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Wearing glasses
Number of subjects: 289
Study: 9146905

Group type: EXPERIMENTAL
Intervention: Sugar alcohols (polyols) in aqueous solutions
Number of subjects: 0
Study: 7712903

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + misoprostol 600 micrograms (Group 1)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + PG05 1 mg vaginal suppository (Group 2)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg + misoprostol 600 micrograms (Group 3)
Number of subjects: 600

Group type: COMPARATOR
Intervention: PG05 group (Group 2)
Number of subjects: 600
Study: 3122551

Group type: EXPERIMENTAL
Intervention: MgCl2 infusate
Number of subjects: 35

Group type: COMPARATOR
Intervention: MgSO4 infusate
Number of subjects: 35
Study: 31096843

Group type: EXPERIMENTAL
Intervention: web-based expert support self-management program (WEST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 29853429

Group type: EXPERIMENTAL
Intervention: Improving dietary quality (measured by the Alternate Health Eating Index - AHEI)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Baseline consumption of carbohydrate, sugars, fibre, magnesium, and AHEI score
Number of subjects: 87
Study: 27931551

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20mg tid, n=50
Number of subjects: 100
Study: 24200748

Group type: EXPERIMENTAL
Intervention: Losartan (50mg daily for 4 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Trichlormethiazide (4mg daily for 4 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normotensive control subjects
Number of subjects: 54
Study: 23332861

Group type: COMPARATOR
Intervention: FF/VI 200/25 μg
Number of subjects: 1224

Group type: COMPARATOR
Intervention: FF/VI 100/25 μg
Number of subjects: 1224

Group type: COMPARATOR
Intervention: VI 25 μg
Number of subjects: 1224

Group type: COMPARATOR
Intervention: FF 200 μg
Number of subjects: 1224